Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Naber

Showing results (171-180 of 195) with videos related to

Pageof 20
Sort By:
Acta Psychiatrica Scandinavica|October 24, 2002
2-COM: an instrument to facilitate patient-professional communication in routine clinical practiceJ van Os, A C Altamura, J Bobes, et al.
Acta Psychiatrica Scandinavica|January 26, 2005
Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophreniaD Naber, M Riedel, A Klimke, et al.
Annals of the New York Academy of Sciences|February 24, 2001
Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's diseaseC Hock, A Maddalena, I Heuser, et al.
Molecular Psychiatry|April 15, 2015
Identification of increased genetic risk scores for schizophrenia in treatment-resistant patientsJ Frank, M Lang, S H Witt, et al.
Molecular Psychiatry|June 4, 2014
Identification of increased genetic risk scores for schizophrenia in treatment-resistant patientsJ Frank, M Lang, S H Witt, et al.
Psychopharmacology|January 1, 1981
Naloxone effects on beta-endorphin, cortisol, prolactin, growth hormone, HVA and MHPG in plasma of normal volunteersD Naber, D Pickar, G C Davis, et al.
International Journal of Psychiatry in Clinical Practice|June 18, 2014
Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapyA C Altamura, C Barnas, I Bitter, et al.
Acta Psychiatrica Scandinavica|August 14, 2008
Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophreniaM Lambert, D Naber, A Schacht, et al.
The American Journal of Psychiatry|February 1, 1981
Behavioral and biological effects of acute beta-endorphin injection in schizophrenic and depressed patientsD Pickar, G C Davis, S C Schulz, et al.
Fortschritte Der Neurologie-Psychiatrie|April 12, 2007
[Clinical standing of valproate treatment of bipolar disorders]H Grunze, M Adli, M Bauer, et al.
Pageof 20

Showing results (171-180 of 195) with videos related to

Sort By:
Pageof 20
Acta Psychiatrica Scandinavica|October 24, 2002
2-COM: an instrument to facilitate patient-professional communication in routine clinical practiceJ van Os, A C Altamura, J Bobes, et al.
Acta Psychiatrica Scandinavica|January 26, 2005
Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophreniaD Naber, M Riedel, A Klimke, et al.
Annals of the New York Academy of Sciences|February 24, 2001
Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's diseaseC Hock, A Maddalena, I Heuser, et al.
Molecular Psychiatry|April 15, 2015
Identification of increased genetic risk scores for schizophrenia in treatment-resistant patientsJ Frank, M Lang, S H Witt, et al.
Molecular Psychiatry|June 4, 2014
Identification of increased genetic risk scores for schizophrenia in treatment-resistant patientsJ Frank, M Lang, S H Witt, et al.
Psychopharmacology|January 1, 1981
Naloxone effects on beta-endorphin, cortisol, prolactin, growth hormone, HVA and MHPG in plasma of normal volunteersD Naber, D Pickar, G C Davis, et al.
International Journal of Psychiatry in Clinical Practice|June 18, 2014
Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapyA C Altamura, C Barnas, I Bitter, et al.
Acta Psychiatrica Scandinavica|August 14, 2008
Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophreniaM Lambert, D Naber, A Schacht, et al.
The American Journal of Psychiatry|February 1, 1981
Behavioral and biological effects of acute beta-endorphin injection in schizophrenic and depressed patientsD Pickar, G C Davis, S C Schulz, et al.
Fortschritte Der Neurologie-Psychiatrie|April 12, 2007
[Clinical standing of valproate treatment of bipolar disorders]H Grunze, M Adli, M Bauer, et al.
Pageof 20